Edoxaban

Edoxaban is the medicine inside Savaysa, a blood thinner taken by mouth. The US label says it is a factor Xa inhibitor approved to cut the chance of stroke and of clots elsewhere in the body in people with nonvalvular atrial fibrillation, and to treat deep vein thrombosis and pulmonary embolism after 5 to 10 days of initial treatment with a parenteral anticoagulant. For the atrial fibrillation use, the label says it should not be used in people with a creatinine clearance above 95 mL/min, because of more ischemic strokes than with warfarin at the highest dose studied.

Also called Savaysa

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 1599538. The openFDA record for NDA 206316 names Daiichi Sankyo as sponsor of the brand Savaysa and lists the original submission as approved on 2015-01-08; the label read here is effective 2025-07-10. A selective factor Xa inhibitor per the label. The claim on this page holds the indications.

Trials at a glance

The figures count the 18 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
18
Phase 3 or 4
14
Recruiting
1
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingNot yet recruitingCompletedTerminatedUnknown statusAll statuses
Phase 2001012
Phase 2/3010012
Phase 30071210
Phase 4112004
All phases12101418

Conditions these trials study

And 2 more.

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 8 more.

About this drug

Level
Substance
Mechanism
A selective inhibitor of factor Xa (US drug label).

Claims and evidence

Context People with nonvalvular atrial fibrillation, or with deep vein thrombosis or pulmonary embolism after initial therapy (US label of SAVAYSA, edoxaban)

Recipient
Recipient not specified
Population
People with nonvalvular atrial fibrillation, and people with deep vein thrombosis or pulmonary embolism who have had 5 to 10 days of initial therapy with a parenteral anticoagulant, restated from the label indications. Other sections of the label were not read.
Care setting
Not stated in the label passages read
Geography
United States (label as published through FDA and openFDA)
Life stage
Not stated in the label passages read (they say patients and give no age)
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (regulatory label)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
Included
None stated
Excluded
None stated
  • Regulatory Evidence stage not applicable Certainty not assessed

    The openFDA record for NDA 206316 names Daiichi Sankyo as the sponsor of SAVAYSA (edoxaban tosylate) and lists an original submission, number 1, as approved on 8 January 2015, in the class Type 1 - New Molecular Entity. The label text read here, effective 10 July 2025, says SAVAYSA is a factor Xa inhibitor with two uses: cutting the risk of both stroke and systemic embolism when nonvalvular atrial fibrillation is present, and treating deep vein thrombosis and pulmonary embolism following 5 to 10 days of initial therapy with a parenteral anticoagulant. For the atrial fibrillation use, the label says it should not be used in patients with a creatinine clearance above 95 mL/min because of an increased risk of ischemic stroke compared with warfarin at the highest dose studied.

    Applies to Recipient not specified People with nonvalvular atrial fibrillation, or with deep vein thrombosis or pulmonary embolism after initial therapy (US label of SAVAYSA, edoxaban)

    Certainty method
    Not assessed
    Limitations
    The label and the openFDA record state what FDA has authorized and how the label words it, not how well the medicine works for any person. openFDA data are unvalidated. Only the indications and mechanism passages of the label were read; doses, contraindications and warnings are not described here, and later label changes are not covered.
    Last checked
    2026-10-30
    Next evidence check due
    Not scheduled
    Sources and citations (7)
    1. Supports FDA drug application NDA206316 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA206316

      Locator
      results[0].application_number
      How it applies
      Quote from the FDA record.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      8b981b3259f7dac7e80f9cd13aa50f5bc729249572085f8bcf4b24a0f1f60d5b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository. It includes product-code and package fields that FDA publishes; records here do not repeat them.
    2. Supports FDA drug application NDA206316 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA206316

      Locator
      results[0].sponsor_name
      How it applies
      Quote from the FDA record.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      8b981b3259f7dac7e80f9cd13aa50f5bc729249572085f8bcf4b24a0f1f60d5b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository. It includes product-code and package fields that FDA publishes; records here do not repeat them.
    3. Supports FDA drug application NDA206316 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA206316

      Locator
      results[0].submissions[6].submission_status_date
      How it applies
      Quote from the FDA record: date of the approved original submission.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      8b981b3259f7dac7e80f9cd13aa50f5bc729249572085f8bcf4b24a0f1f60d5b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository. It includes product-code and package fields that FDA publishes; records here do not repeat them.
    4. Supports FDA drug application NDA206316 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA206316

      Locator
      results[0].submissions[6].submission_class_code_description
      How it applies
      Quote from the FDA record.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      8b981b3259f7dac7e80f9cd13aa50f5bc729249572085f8bcf4b24a0f1f60d5b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository. It includes product-code and package fields that FDA publishes; records here do not repeat them.
    5. Supports FDA drug application NDA206316 (openFDA Drugs@FDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29. · NDA: NDA206316

      Locator
      results[0].submissions[6].submission_status
      How it applies
      Quote from the FDA record: AP is the approved status.
      Retrieved
      Source effective date
      2026-10-29
      Source state
      Current
      Version fingerprint
      8b981b3259f7dac7e80f9cd13aa50f5bc729249572085f8bcf4b24a0f1f60d5b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository. It includes product-code and package fields that FDA publishes; records here do not repeat them.
    6. Supports SAVAYSA drug label (openFDA record, set id e77d3400-56ad-11e3-949a-0800200c9a66)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250710 (label version 28), dataset last updated 2026-10-30. · SPL set id: e77d3400-56ad-11e3-949a-0800200c9a66

      Locator
      results[0].indications_and_usage[0]
      How it applies
      Quote from the label: the indications and the limitation of use.
      Retrieved
      Source effective date
      2025-07-10
      Source state
      Current
      Version fingerprint
      a28b87c253a1cdabc0bab935072a07917d894b9651865db276f06dc2e49ccbff
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw file is committed in the atlas repository. A second copy was fetched 2026-11-09; its bytes differ from the 2026-10-30 copy. The 2026-11-09 copy is committed in the atlas repository.
    7. Supports SAVAYSA drug label (openFDA record, set id e77d3400-56ad-11e3-949a-0800200c9a66)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250710 (label version 28), dataset last updated 2026-10-30. · SPL set id: e77d3400-56ad-11e3-949a-0800200c9a66

      Locator
      results[0].openfda.brand_name[0]
      How it applies
      Quote from the label record.
      Retrieved
      Source effective date
      2025-07-10
      Source state
      Current
      Version fingerprint
      a28b87c253a1cdabc0bab935072a07917d894b9651865db276f06dc2e49ccbff
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw file is committed in the atlas repository. A second copy was fetched 2026-11-09; its bytes differ from the 2026-10-30 copy. The 2026-11-09 copy is committed in the atlas repository.

FDA label

Assembled by a program from the openFDA drug label dataset, retrieved 8 November 2026, for the products that contain this drug: the label of the application holder or its company group, never a repackager's. Data provided by the U.S. Food and Drug Administration (open.fda.gov). The label is a manufacturer's submission that FDA has not verified, and the label on the product may differ. 1 label below.

SAVAYSA

Application
NDA206316
Labeler
Daiichi Sankyo Inc.
Label version
Version 28, effective
Label set id
e77d3400-56ad-11e3-949a-0800200c9a66
Boxed warning
Yes
Sections the label has
Indications and usage Contraindications Warnings and cautions Adverse reactions Drug interactions Use in specific populations Pregnancy Pediatric use Geriatric use Clinical pharmacology Clinical studies

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA206316 SAVAYSA
  2. Supplemental approval NDA206316 SAVAYSA
  3. Supplemental approval NDA206316 SAVAYSA
  4. Supplemental approval NDA206316 SAVAYSA
  5. Supplemental approval NDA206316 SAVAYSA

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 1

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 4 efficacy supplement approvals on record.

    ProductNDA206316

Registry trials 18

Record details

Record id
cardio:edoxaban
Content hash
2991ce8be149c6d685bc700b8fe14b43a0f9b2e7c1d970a4a7438c0e0578ce74